LaBranche & — Merger or Acquisition (May 2011)
26 slides from LaBranche &'s merger presentation, May 13, 2011
Slide 1: Presentation on the Proposed Combination of Cowen Group and LaBranche & Co.
Cowen Group, Inc. Presentation on the Proposed Combination of Cowen Group, Inc. and LaBranche & Co. Inc. May 2011 CONFIDENTIAL
Slide 2: Disclaimer - Important Information For Investors And Stockholders
Disclaimer - Important Information For Investors And Stockholders CONFIDENTIAL This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction involving Cowen Group, In
Slide 3: Cautionary Notice Regarding Forward-Looking Statements
Cautionary Notice Regarding Forward-Looking Statements CONFIDENTIAL This presentation contains a number of forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that are not limited to historical facts, but reflect LaBranc
Slide 4: Transaction Highlights
Transaction Highlights Exchange Ratio Fixed Ratio of 0.9980 COWN Class A Common Stock for each share of LAB Common Stock Implied 16% premium LAB closing price on 2/16/11 Ownership 64.9% Cowen / 35.1% LaBranche 66.2% Cowen / 33.8% LaBranche (fully diluted) Accretion Expected to be accretive in 2012 S
Slide 5: About the Company
CONFIDENTIAL About the Company 3
Slide 6: Company Overview
Alternative Investments Alternative Solutions Real Estate Cowen Healthcare Royalty Partners Firm Capital ~ $460 million in equity at 3/31/11 Significant portion is invested alongside Ramius investment management clients Since 1999, Ramius has generated a gross compounded annualized return on its pro
Slide 7: Company Strengths
Company Strengths Research-driven investment bank positioned for success following an operating turnaround Focused on the underserved needs of emerging-growth clients in the United States and China Alternative investment management platform poised to benefit from continued growth in investor allocat
Slide 8: Significant Progress at Cowen and Company Since Merger with Ramius
Significant Progress at Cowen and Company Since Merger with Ramius Invested in new business initiatives to increase product capabilities of capital markets team Established a debt capital markets group and developed convertible origination and distribution capability, while increasing and re-focusin
Slide 9: Public Equity Underwriting (IPOs & Follow-Ons) – Showing Progress
Public Equity Underwriting (IPOs & Follow-Ons) – Showing Progress Analysis includes transactions in Cowen and Company’s core sectors only Source: ECM Analytics. Note: Excludes issuers above $5bn in market cap and transactions below $10m in proceeds. Includes Wall-Cross Follow-On transactions. CONFID
Slide 10: Sales & Trading
Sales & Trading Top-ranked equity sales & trading organization working closely with Research to provide superior aftermarket support Expanding product offerings, including building on existing electronic platform to attract new accounts and gain share among existing client base Electronic Products G
Slide 11: Sales & Trading Market Share
Sales & Trading Market Share CONFIDENTIAL Trading of All U.S. Equities (Excluding Bulletin Board) – Ranking by Volume Source:Bloomberg. Volume shown includes: Active Domestic Common Stock, ADR's, REIT's, Warrent's and Right's traded on the NYSE and NASDAQ GS, GM & CM securities excluding Pink Sheets
Slide 12: Research Group: Footprint
CONFIDENTIAL Financial Institutions Aerospace & Defense Alternative Energy Healthcare Telecommunications Technology Consumer Research Group: Footprint Our primary focus is on growth industry verticals and we closely follow over 400 companies. Aerospace & Defense: Cai von Rumohr & Gautam Khanna REITs
Slide 13: Research Group
Research Group Created the Cowen Emerging Company Research product to cover underserved companies with a market cap <$250 million with a focus on the Health Care sector Supports pledge to provide research coverage to all companies for which Cowen raises capital Recent hires in Health Care research f
Slide 14: Alternative Investment Management Overview
CONFIDENTIAL Alternative Investment Management Overview Ramius has approximately $9.7 billion* of assets under management across a predominantly institutional client base Investment platform built across a strategic range of asset classes and investment strategies Extensive experience and track reco
Slide 15: Successfully Adapted To Market Changes And Investor Needs
CONFIDENTIAL Successfully Adapted To Market Changes And Investor Needs Ramius reorganized platform Re-focused the product and service offerings to meet client demand Launched Ramius Trading Strategies - managed account fund of funds platform focusing on managed futures/global macro Healthcare Royalt
Slide 16: Alternative Investment Management Overview
CONFIDENTIAL HEALTHCARE ROYALTY PARTNERS4 $1.0 Billion Alternative Investment Management Overview ALTERNATIVE INVESTMENTS $1.4 Billion Invested Firm Capital (~$400 Million) ALTERNATIVE SOLUTIONS $3.2 Billion RAMIUS LLC REAL ESTATE $1.6 Billion 1. All assets under management as of April 1, 2011 inclu
Slide 17: Global Hedge Fund Assets Under Management - Poised For Growth
Global Hedge Fund Assets Under Management - Poised For Growth Source of graph data: Casey Quirk, The Bank of New York Mellon, Barclays Per Deutsche Bank 2011 Alternative Investment Survey, investors expect to reduce cash positions significantly in 2011 while expecting inflows into hedge funds to be
Slide 18: Investment Portfolio has Over $380 Million in Equity
Investment Portfolio has Over $380 Million in Equity CONFIDENTIAL At March 31, 2011, Cowen’s balance sheet included ~$460 million in equity Since the firm began investing its own capital in 1999, Ramius has generated a gross compounded annualized return on its proprietary equity capital (ROE) of 17.
Slide 19: Historical Returns on Invested Proprietary Capital vs. S&P 500
Historical Returns on Invested Proprietary Capital vs. S&P 500 Beginning in 1999, Ramius has generated a gross compounded annualized return on its proprietary equity capital (ROE) of 17.3%* versus the S&P 500 return of 2.4%**. CONFIDENTIAL * The 17.3% return represents a gross calculation on a CAGR
Slide 20: About the Company
CONFIDENTIAL About the Company 18
Slide 21: Company Overview
Company Overview A public company traded on NYSE (ticker LAB) LaBranche was established in 1924 as one of NYSE’s first specialist institutions; expanded over 85 years to cover a global suite of financial products LaBranche is based in New York with satellite offices in London and Hong Kong Recently
Slide 22: Company Overview (Cont'd)
Company Overview (Cont’d) Market Making Activities LABRANCHE (NYSE: LAB) Proprietary Technology CONFIDENTIAL Additional Opportunities Global ETF platform With professionals in New York, London and Hong Kong, LaBranche provides global coverage and liquidity in a comprehensive set of ETF products worl
Slide 23: About the Merger
CONFIDENTIAL About the Merger 21
Slide 24: Cowen/LaBranche Combination Will Improve Shareholder Value
We Believe the Cowen/LaBranche Combination Will Improve Shareholder Value for Combined Company Creates a larger, more robust sales & trading platform positioned for growth Increases capital base to generate attractive risk-adjusted returns Increases capital markets footprint in China Realize certain
Slide 25: Appendix
l COWEN Appendix CCONDENTIAL 24
Slide 26: Cowen Group, Inc. Financial Highlights 1Q 2011 vs 1Q 2010
CONFIDENTIAL Cowen Group, Inc. Financial Highlights 1Q 2011 vs 1Q 2010: Economic Income(1) CONFIDENTIAL (1) Economic Income/(Loss) and Economic Income/(Loss) excluding certain non-cash items are non-GAAP measures. The Company believes that these non-GAAP measures, viewed in addition to and not in li